⚠️ Neutral
Listed
Pharmaceuticals & Biotechnology
Symbiotec Pharmalab Limited IPO
₹1,757 Cr · Fresh Issue & OFS · Pharmaceuticals & Biotechnology
Price Band
₹938 – ₹988
GMP (Grey Market)
—
No GMP data yet
Issue Size
₹1,757 Cr
Fresh Issue & OFS
Market Cap
₹6,244.43 Cr
At upper band
P/E Ratio
56.8x
P/S: 7.2x
Listing Date
01 Sep 2026
BSE & NSE
IPO Timeline
✓
Opens
24 Aug 2026
✓
Closes
27 Aug 2026
✓
Allotment
28 Aug 2026
✓
Refund
31 Aug 2026
✓
Listing
01 Sep 2026
IPO India Hub: Neutral
Conviction
5/10
The company trades at 1.42× sector midpoint with a 56.8x P/E, placing it within Subscribe range on valuation alone. However, weak profit growth (4.8% PAT CAGR), low ROCE of 11.8%, and a 91.4% OFS component—where promoters are exiting—create material execution and governance concerns that offset valuation appeal.
Listing Performance
Issue Price
₹988
Allotment price
Listing Price
₹978.2
-0.99% on listing day
Current Price (CMP)
₹1274
+28.9% vs issue
Listed On
01 Sep 2026
BSE & NSE
Our Analysis — Key Points
✓ Strength
Strong EBITDA margin and scale
The company maintains a healthy 27.26% EBITDA margin and generated ₹872.3 Cr in FY0 revenue, indicating operational efficiency in a capital-intensive pharma sector. This margin profile supports the current valuation multiple relative to peers.
✓ Strength
Valuation within sector midpoint
At 1.42× the Healthcare/Diagnostics sector midpoint of 40×, the P/E ratio sits comfortably within the Subscribe threshold of ≤1.5× for profitable companies. The 7.2x P/S is also reasonable for a mid-cap pharma player with established revenue.
⚠ Risk
Weak profit growth trajectory
PAT CAGR of only 4.8% over two years, with net profit actually declining from ₹100.1 Cr (FY-2) to ₹96.8 Cr (FY-1) before recovering to ₹109.9 Cr (FY0), signals margin pressure or operational headwinds. This growth rate is well below the 20% threshold expected for conviction in IPO valuations.
⚠ Risk
Massive promoter exit via OFS
91.4% of the ₹1,757 Cr issue is OFS, meaning promoters are selling existing shares rather than the company raising fresh capital. Promoter holding drops from 36.39% to 33.28% post-issue, signaling reduced skin-in-the-game at a critical juncture and raising questions about insider confidence.
⚠ Risk
Low ROCE and capital efficiency
ROCE of 11.8% is below the cost of capital for most investors and well below pharma sector norms of 15–20%, indicating the company is not generating adequate returns on deployed capital. This undermines the quality of earnings despite the margin profile.
₹ Valuation
Fair valuation offset by growth concerns
The 56.8x P/E at 1.42× sector midpoint is technically within Subscribe range, but NPM of 12.6% (below the 15% threshold for margin justification) combined with 4.8% PAT CAGR means the market is pricing in growth that the company has not delivered. Investors are paying for potential, not proven momentum.
👁 Watch
Post-listing capital allocation and debt reduction
Monitor whether management uses the ₹112.5 Cr debt repayment (45% of net proceeds) to materially improve ROCE and reduce leverage, or whether capital discipline remains weak. This will be the key test of management quality and future shareholder returns.
Top Analyst Reviews
| Analyst / Firm | Rating | Known For | Review |
|---|---|---|---|
| IPO India Hub Our independent review |
Original analysis based on DRHP & public financials | This page | |
| Dilip Davda Chittorgarh.com |
India's most followed independent IPO analyst | Search on Chittorgarh → | |
| Capital Market (CM Rating) CapitalMarket.com |
Widely-cited "New Issue Monitor" reports | Search on CapitalMarket → | |
| ICICI Securities ICICIdirect Research |
SEBI-registered broker research desk | Visit ICICIdirect → | |
| IPO Guru Analyst Leaderboard ipoguru.in |
Ranks 49 analysts by real IPO outcome accuracy | View leaderboard → |
External links go to each platform's IPO section — search for "Symbiotec Pharmalab Limited" to find the specific review. IPO India Hub does not represent the accuracy of third-party ratings.
Company Snapshot
Revenue
₹869.15 Cr
Net Profit
₹109.90 Cr
Industry
Pharmaceuticals & Biotechnology
Issue Type
Fresh Issue & OFS
Promoters
ANIL SATWANI, KASHISH SATWANI, SUSHIL SATWANI AND SATWANI HOLDINGS LLP
Lead Managers
JM Financial, Avendus Capital, Motilal Oswal Investment Advisors and Nomura Financial Advisory
Quick Actions
Frequently Asked Questions
Neutral. The company trades at 1.42× sector midpoint with a 56.8x P/E, placing it within Subscribe range on valuation alone. However, weak profit growth (4.8% PAT CAGR), low ROCE of 11.8%, and a 91.4% OFS component—where promoters are exiting—create material execution and governance concerns that offset valuation appeal.
GMP data is not yet available for this IPO. Check our GMP Live page for the latest updates closer to the listing date.
Lot size details will be updated when the DRHP is filed. The price band is ₹938 – ₹988.
The IPO opens on 24 Aug 2026. It closes on 27 Aug 2026. Allotment is expected on 28 Aug 2026. Refunds initiate on 31 Aug 2026. Listing on BSE and NSE is on 01 Sep 2026.
The lead managers for the IPO are JM Financial, Avendus Capital, Motilal Oswal Investment Advisors and Nomura Financial Advisory. Check the SEBI filing for the registrar details.
The IPO listed on 01 Sep 2026 at ₹978.2 against an issue price of ₹988 (-0.99% on listing day). The current market price (CMP) is approximately ₹1274 (28.9% vs issue).
Our analysis is <strong>Neutral</strong>. Consider applying selectively before the issue closes on 27 Aug 2026. The company trades at 1.42× sector midpoint with a 56.8x P/E, placing it within Subscribe range on valuation alone. However, weak profit growth (4.8% PAT CAGR), low ROCE of 11.8%, and a 91.4% OFS component—where promoters are exiting—create material execution and governance concerns that offset valuation appeal.
Our analysis is <strong>Neutral</strong>. Consider applying selectively before the issue closes on 27 Aug 2026. The IPO is priced at a P/E of 56.8x. Market cap at issue price is ₹6,244.43 Cr. As with all IPOs, please read the DRHP and assess your own risk tolerance before investing.
You can apply via UPI through your broker's trading app (Zerodha, Upstox, Fyers, etc.) or via ASBA through your net banking portal. The issue closes on 27 Aug 2026, so apply before that date. Step 1: Log in to your broker or bank app. Step 2: Go to IPO section and search for 'Symbiotec Pharmalab Limited'. Step 3: Enter the number of lots and UPI ID. Step 4: Accept the mandate on your UPI app.
Explore More